ArticleCancer science2014
Tumor miR-125b predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection.
Article in Cancer science, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Systematic Analysis of microRNA Biomarkers for Diagnosis, Prognosis, and Therapy in Patients With Clear Cell Renal Cell Carcinoma.Frontiers in oncology · 2020Pooled it
- MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis.Oncotarget · 2015Pooled it
- miR-125 in Breast Cancer Etiopathogenesis: An Emerging Role as a Biomarker in Differential Diagnosis, Regenerative Medicine, and the Challenges of Personalized Medicine.Non-coding RNA · 2024Review
- Characterizing the molecular heterogeneity of clear cell renal cell carcinoma subgroups classified by miRNA expression profile.Frontiers in molecular biosciences · 2022Article
- Review
- MicroRNA Signature in Renal Cell Carcinoma.Frontiers in oncology · 2020Review
- Molecular Mechanisms in Clear Cell Renal Cell Carcinoma: Role of miRNAs and Hypermethylated miRNA Genes in Crucial Oncogenic Pathways and Processes.Frontiers in genetics · 2019Review
- miR-125b is associated with renal cell carcinoma cell migration, invasion and apoptosis.Oncology letters · 2017Article
- miRNAs in Prediction of Prognosis in Clear Cell Renal Cell Carcinoma.BioMed research international · 2017Review
- The microRNA signatures: aberrantly expressed microRNAs in head and neck squamous cell carcinoma.Journal of human genetics · 2017Review
- Article
- Diagnostic and prognostic accuracy of miR-21 in renal cell carcinoma: a systematic review protocol.BMJ open · 2016Article
- EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma.Nature communications · 2015Article
- MicroRNA expression profiles in muscle-invasive bladder cancer: identification of a four-microRNA signature associated with patient survival.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- MicroRNAs in clear cell renal cell carcinoma: biological functions and applications.Journal of kidney cancer and VHL · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aims to evaluate the impact of tumor microRNA-125b (miR-125b) on recurrence and survival of patients with clear-cell renal cell carcinoma (ccRCC) following surgery. We retrospectively enrolled 276 patients (200 in the training cohort and 76 in the validation cohort) with ccRCC undergoing nephrectomy at a single institution. Clinicopathologic features, cancer-specific survival (CSS) and recurrence-free survival (RFS) were recorded. Tumor miR-125b levels were assessed by in situ hybridization (ISH) in specimens of patients. The Kaplan-Meier method was applied to compare survival curves. Cox regression models were used to analyze the impact of prognostic factors on CSS and RFS. A concordance index (C-index) was calculated to assess predictive accuracy. In both cohorts, tumor miR-125b positively correlated with Fuhrman grade. High tumor miR-125b indicated poor survival and early recurrence for patients with ccRCC, especially with advanced stage disease. After multivariable adjustment, tumor miR-125b was identified as an independent adverse prognostic factor for survival and recurrence. The predictive accuracy of traditional TNM and UCLA Integrated Staging System prognostic models was improved when tumor miR-125b was added. The results showed that tumor miR-125b is a potential independent adverse prognostic biomarker for recurrence and survival of patients with ccRCC after nephrectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.